Cargando…

Burn Center Organization and Cellular Therapy Integration: Managing Risks and Costs

The complex management of severe burn victims requires an integrative collaboration of multidisciplinary specialists in order to ensure quality and excellence in healthcare. This multidisciplinary care has quickly led to the integration of cell therapies in clinical care of burn patients. Specific a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chemali, Michèle, Laurent, Alexis, Scaletta, Corinne, Waselle, Laurent, Simon, Jeanne-Pascale, Michetti, Murielle, Brunet, Jean-François, Flahaut, Marjorie, Hirt-Burri, Nathalie, Raffoul, Wassim, Applegate, Lee Ann, de Buys Roessingh, Anthony S, Abdel-Sayed, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483250/
https://www.ncbi.nlm.nih.gov/pubmed/33970273
http://dx.doi.org/10.1093/jbcr/irab080
Descripción
Sumario:The complex management of severe burn victims requires an integrative collaboration of multidisciplinary specialists in order to ensure quality and excellence in healthcare. This multidisciplinary care has quickly led to the integration of cell therapies in clinical care of burn patients. Specific advances in cellular therapy together with medical care have allowed for rapid treatment, shorter residence in hospitals and intensive care units, shorter durations of mechanical ventilation, lower complications and surgery interventions, and decreasing mortality rates. However, naturally fluctuating patient admission rates increase pressure toward optimized resource utilization. Besides, European translational developments of cellular therapies currently face potentially jeopardizing challenges on the policy front. The aim of the present work is to provide key considerations in burn care with focus on architectural and organizational aspects of burn centers, management of cellular therapy products, and guidelines in evolving restrictive regulations relative to standardized cell therapies. Thus, based on our experience, we present herein integrated management of risks and costs for preserving and optimizing clinical care and cellular therapies for patients in dire need.